CDH3 and cancer: Epigenetic alternations of CDH3 with concurrent alterations in CDH3 protein expression have been correlated with adverse histopathology in a variety of cancers, such as breast, cervical, ovarian, pancreatic, gall bladder, colorectal, hepatocellular, and oral squamous cancers [18,19,20,21,22,23,24,25].